Company intelligence / Profile preview

Celgenyx

Hangzhou, Zhejiang, Chinaventureradar.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Celgenyx develops next-generation, off-the-shelf cell immunotherapies for malignant cancers using PBMC-derived and iPSC-differentiated immune cells engineered with chimeric antigen receptors and novel target identification. The company recently completed a $14M Series A to support R&D and construction of a GMP pilot production base. No clinical results have been reported as of the latest updates.[1][3]

Therapeutic areas: Oncology
Modalities: Cell therapies (PBMC-derived immune cells expressing CAR)iPSC-differentiated immune cell products (off-the-shelf)
Industry: Biotech

Beyond the preview

Go deeper on Celgenyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celgenyx.

Explore the full profile